1YR企业会员
| 英文名称 | 中文名称 | CAS |
|---|---|---|
| Dehydroepiandrosterone sulfate | 硫酸脱氢表雄酮 | 651-48-9 |
| 8-Azahypoxanthine | 8-氮杂次黄嘌呤 | 2683-90-1 |
| Sirukumab (anti-IL-6) | SIRUKUMAB ( 西鲁库单抗 ) | 1194585-53-9 |
| Bimagrumab (anti-ACVR2B) | Bimagrumab | 1356922-05-8 |
| Ulocuplumab (anti-CXCR4) | Ulocuplumab | 1375830-34-4 |
| Abelacimab(anti-Factor XI) | Abelacimab | 2098724-83-3 |
| Tesnatilimab (anti-NKG2D) | 特拉佐利单抗 | 2242758-08-1 |
| Zansecimab (anti-ANGPT2) | ZANSECIMAB (ANTI-ANGPT2) | 2415205-37-5 |
| Meropenem-d6 | 美罗培南-d6 | 1133424-00-6 |
| Ranibizumab (anti-VEGFA) | 雷尼株单抗 | 347396-82-1 |
| 2-(azetidin-1-yl)ethan-1-amine | 2-(氮杂环丁烷-1-基)乙-1-胺 | 795299-77-3 |
| Enoblituzumab (anti-CD276) | MGA271 | 1353485-38-7 |
| Flanvotumab (anti-TYRP1) | Flanvotumab | 1188277-05-5 |
| Bermekimab (anti-IL-1a) | BERMEKIMAB (贝迈奇单抗 ) | 1401965-15-8 |
| Prezalumab (anti-B7-H2) | Prezalumab | 1523164-68-2 |
| Depatuxizumab mafodotin (anti-EGFR) | Depatuxizumab Mafodotin | 1585973-65-4 |
| Tinurilimab (anti-CEACAM6) | 替奴瑞利单抗 | 2226224-30-0 |
| Vandortuzumab (anti-STEAP1) | 万多妥珠单抗 | 1557989-52-2 |
| Galiximab (anti-CD80) | 加利昔单抗 | 357613-77-5 |
| Ethyl 2-oxo-4-phenylbutyrate | 2-氧代-4-苯基丁酸乙酯 | 64920-29-2 |
| Pascolizumab (anti-IL-4) | Sb-240683 | 331243-22-2 |
| Ocrelizumab (anti-CD20) | Ocrelizumab | 637334-45-3 |
| Bis(hexamethylene)triamine | 双(六甲撑)三胺 | 143-23-7 |
| Ixekizumab (anti-CTLA-8) | 伊西贝单抗 | 1143503-69-8 |
| Enokizumab (anti-IL-9) | ENOKIZUMAB ( 依诺凯组单抗 ) | 909875-08-7 |
| Concizumab (anti-TFPI) | Concizumab | 1312299-39-0 |
| Tarextumab (anti-NOTCH3) | Tarextumab | 1359940-55-8 |
| Emibetuzumab (anti-MET) | Emibetuzumab | 1365287-97-3 |
| Tesidolumab (anti-Complement C5) | Tesidolumab | 1531594-08-7 |
| Xentuzumab (anti-IGF1) | 珍妥珠单抗 | 1417158-65-6 |
| Lacnotuzumab (anti-M-CSF) | Lacnotuzumab | 1831128-32-5 |
| Ladiratuzumab (anti-SLC39A6) | LADIRATUZUMAB (ANTI-SLC39A6) | 1629760-28-6 |
| Narsoplimab (anti-MASP2) | NARSOPLIMAB (纳索利单抗 ) | 2108782-45-0 |
| Belimumab (anti-TNFSF13B) | 贝利木单抗 | 356547-88-1 |
| IDO-IN-13 | GS-4361 | 2291164-02-6 |
| Benzyldiphenylphosphine | 苄基二苯基膦 | 7650-91-1 |
| Alizarin Yellow R sodium salt | 茜素黄R钠盐 | 1718-34-9 |
| Eldelumab (anti-CXCL10) | Eldelumab | 946414-98-8 |
| Tisotumab (anti-F3) | Tisotumab | 1418628-81-5 |
| Vopratelimab (anti-ICOS) | 伏派利单抗 | 2039148-04-2 |
| Ragifilimab (anti-TNFRSF18) | 拉格芙利单抗 | 2207590-51-8 |
| Daclizumab (anti-IL2RA) | 达昔单抗 | 152923-56-3 |
| Sonepcizumab (anti-Sphingosine-1-phosphate) | SONEPCIZUMAB (ANTI-SPHINGOSINE-1-PHOSPHATE) | 1031360-18-5 |
| XP-59 | XP-59 | 890402-73-0 |
| Urea-13C | 尿素-13C | 58069-82-2 |
| Rilotumumab (anti-HGF) | RILOTUMUMAB ( 利妥木单抗 ) | 872514-65-3 |
| Narnatumab (anti-RON) | Narnatumab | 1188275-92-4 |
| Carotuximab (anti-CD105) | Carotuximab | 1268714-50-6 |
| Brazikumab (anti-IL-23) | Brazikumab | 1610353-18-8 |
| Ontamalimab (anti-MADCAM1) | Ontamalimab | 2098790-40-8 |
| Dostarlimab (anti-PD-1) | Dostarlimab | 2022215-59-2 |
| Avdoralimab (anti-C5AR1) | AVDORALIMAB (艾朵利单抗 ) | 2226393-85-5 |
| Datopotamab (anti-TROP2) | DATOPOTAMAB (ANTI-TROP2) | 2267989-53-5 |
| Mogamulizumab (anti-CCR4) | Mogamulizumab | 1159266-37-1 |
| Rosmantuzumab (anti-RSPO3) | Rosmantuzumab | 1684393-04-1 |
| Ianalumab (anti-TNFRSF13C) | Ianalumab | 1929549-92-7 |
| Quetmolimab (anti-CX3CL1) | QUETMOLIMAB (奎莫利单抗 ) | 2084037-83-0 |
| Gemtuzumab (anti-CD33) | 吉妥珠单抗奥唑米星 | 220578-59-6 |
| Telazorlimab (anti-TNFRSF4) | 特拉佐利单抗 | 2126777-87-3 |
| Imazapic | 甲咪唑烟酸 | 104098-48-8 |
| Guselkumab (anti-IL-23) | 古塞库单抗 | 1350289-85-8 |
| Labetuzumab govitecan (anti-CEACAM5) | Labetuzumab Govitecan | 1469876-18-3 |
| Apamistamab (anti-PTPRC) | Iodine (131I) Apamistamab | 2097132-02-8 |
| Sirtratumab (anti-SLITRK6) | Sirtratumab | 1824663-82-2 |
| Nadecnemab (anti-GFRA3) | NADECNEMAB (ANTI-GFRA3) | 2377679-19-9 |
| Dysprosium(III) trifluoromethanesulfonate | 三氟甲烷磺酸镝 | 139177-62-1 |
| Efalizumab (anti-ITGAL) | EFALIZUMABUM | 214745-43-4 |
| (W) Phenyldichlorosilane | 苯基二氯硅烷 | 1631-84-1 |
| Elotuzumab (anti-SLAMF7) | 埃罗妥珠单抗 | 915296-00-3 |
| Oxelumab (anti-TNFSF4) | OXELUMAB ( 奥塞芦单抗 ) | 1186098-83-8 |
| Seribantumab (anti-ERBB3) | Seribantumab | 1334296-12-6 |
| Zagotenemab (anti-Tau) | 泽格特奈单抗 | 2019133-28-7 |
| Bexmarilimab (anti-STAB1) | BEXMARILIMAB | 2259301-27-2 |
| Lemzoparlimab (anti-CD47) | 来佐利单抗 | 2377483-71-9 |
| Enfortumab (anti-NECTIN4) | ENFORTUMAB (ANTI-NECTIN4) | 1448664-46-7 |
| KWAR23 (anti-SIRPg) | KWAR23 (ANTI-SIRPG) | 2243227-60-1 |
| Lexatumumab (anti-TNFRSF10B) | 来沙木单抗 | 845816-02-6 |
| Bivatuzumab (anti-CD44v6) | 比伐珠单抗 | 214559-60-1 |
| Urelumab (anti-TNFRSF9) | 乌瑞芦单抗 | 934823-49-1 |
| Dinutuximab (anti-GD2) | dinutuximab | 1363687-32-4 |
| Ravulizumab (anti-Complement C5) | Immunoglobulin G2/G4, anti-(human complement C5) (human-Mus musculus ALXN1210 heavy chain), disulfide with human-Mus musculus ALXN1210 κ-chain, dimer | 1803171-55-2 |
| Apelin 17 TFA | Apelin 17 TFA,Apelin受体（APJ）激动剂 | 217082-57-0 |
| Lumiliximab (anti-FceR2) | LUMILIXIMAB ( 鲁昔单抗 ) | 357613-86-6 |
| Otilimab (anti-GM-CSF) | 对照抗体 | 1638332-55-4 |
| Fulranumab (anti-NGF) | FULRANUMAB ( 福拉奴单抗 ) | 902141-80-4 |
| Vorsetuzumab (anti-CD70) | Vorsetuzumab | 1165740-62-4 |
| Vantictumab (anti-FZD) | 万替妥单抗 | 1345009-45-1 |
| Indusatumab (anti-GUCY2C) | 英度妥单抗 | 1497400-26-6 |
| Tamrintamab (anti-DPEP3) | TAMRINTAMAB (他林妥单抗 ) | 2148325-59-9 |
| Cinpanemab (anti-Alpha-synuclein) | CINPANEMAB (辛帕奈单抗 ) | 2094516-02-4 |
| Daxdilimab (anti-ILT7) | 达司迪利单抗 | 2245966-28-1 |
| Idactamab (anti-SLC1A5) | IDACTAMAB (ANTI-SLC1A5) | 2245205-37-0 |
| Ponsegromab (anti-GDF15) | PONSEGROMAB | 2368950-15-4 |
| Gevokizumab (anti-IL-1b) | 吉伏组单抗 | 1129435-60-4 |
| Itolizumab (anti-CD6) | 伊利组单抗 | 1116433-11-4 |
| Girentuximab (anti-CA9) | 吉妥昔单抗 | 916138-87-9 |
| Codrituzumab (anti-GPC3) | 考曲妥珠单抗 | 1365267-33-9 |
| Vunakizumab (anti-IL-17a) | Vunakizumab | 1792181-33-9 |
| Imaprelimab (anti-CD146) | 伊普利单抗 | 2014343-04-3 |
| Serplulimab (anti-PDCD1) | SERPLULIMAB (斯鲁利单抗 ) | 2231029-82-4 |
联系方式
